Menu

About Us

Cambia is an independent non-profit institute creating new technologies, tools and paradigms to promote change and enable innovation.

Read More

Homologous telomerase gene sequences

This group of patents – three of which are owned by Geron and University of Colorado (individually or jointly), one of which is co-owned by Geron and Albert Einstein College of Medicine, and one of which is owned by Research & Development Institute in Montana – concern nucleic acid sequences and gene products of telomerase from other species.  By no means does this group exhaust the species from which telomerase gene has been cloned; telomerase from other species can be found in the scientific literature.

The species represented in this group are:

Patent Data Title and relevant claims Family Data
US 6,093,809

Assignee:

University Technology Corp.

Geron Corp.

Earliest priority:

01 Oct 1996

Filed:

06 May 1997

Granted:

25 Jul 2000

Expiry date:

01 Oct 2016

 Telomerase

Claim 1:  An isolated polynucleotide consisting of the nucleic acid sequence shown in SEQ. ID. No. 1.

No other claims.

 No functionally related patents or applications – published in English
US 6,166,178

Assignee:

University Technology Corp.

Geron Corp.

Earliest priority:

01 Oct 1996

Filed:

19 Nov 1997

Granted:

26 Dec 2000

Expiry date:

01 Oct 2016

 Telomerase catalytic subunit

Claim 1:  An isolated polypeptide consisting of the amino acid sequence shown in SEQ ID. NO. 110.

No other claims.

 No functionally related patents or applications – published in English
US 6,309,867

Assignee:

University Technology Corp.

Earliest priority:

01 Oct 1996

Filed:

29 Oct 1999

Granted:

30 Oct 2001

Expiry date:

01 Oct 2016

 Telomerase

Claim 1:  An isolated polypeptide consisting of the amino acid sequence shown in SEQ. ID. NO. 69.

No other claims

 No functionally related patents or applications – published in English
US 6,541,202

Assignee:

Research &

Development Institute

Filed:

13 Oct 1999

Granted:

01 Apr 2003

Expiry date:

13 Oct 2019

 Telomerase reverse transcriptase (TERT) genes from Candida albicans

Claim 1:  An isolated nucleic acid molecule having at least 80% identity to a polynucleotide molecule that encodes the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 4, wherein said nucleic acid molecule encodes an amino acid sequence having telomerase reverse transcriptase activity.

 AU 2000/80023 A5

US 2003/134275 A1

W0 01/27287 A1
US 6,767,719

Assignee:

Geron Corp.

Albert Einstein College of Medicine

Earliest priority:

26 Nov 1997

Filed:

16 Mar 1998

Granted:

27 Jul 2004

Expiry date:

26 Nov 2017 *

 Mouse telomerase reverse transcriptase

Claim 1:  An isolated, purified or recombinant polynucleotide encoding a telomerase reverse transcriptase protein, wherein said protein: (i) has at least 90% sequence identity to SEQ. ID NO:2; (ii) has telomerase catalytic activity when associated with telomerase RNA component; and (iii) contains at least one of the following amino acid motifs; Motif T: W-X12 -FFY-X1 -TE-X11 -R-X3 -W; Motif 1: LR-X1 -IPK; Motif 2: R-X1 -I-X15 -K; Motif A: P-X3 -F-X3 -D-X4 -YD; Motif B: Y-X4 -G-X2 -QG-X3 -S; Motif C: DD-X1 -L; or Motif D: A-X2 -F-X18 -K; wherein Xn is a sequence of unspecified amino acids of length “n”.

 See Appendix 1 for complete list.

No applications or patents filed outside of U.S. with claims to mouse TERT

* – A terminal disclaimer was filed for this patent.  Without obtaining the full prosecution history of this patent to reveal which patent it was disclaimed in favor of, certainty of the expiry date is not possible.

[1] An interference is a procedure conducted by the United States Patent and Trademark Office when multiple applications have identical claims.  The purpose of an interference is to determine who was the first-in-time inventor and so deserves the patent.

[2] For a review of hybridization, see www.roche-applied-science.com/PROD_INF/MANUALS/InSitu/pdf/ISH_33-37.pdf.

[3] Geron has many pending patent applications on telomerase, some of which may contain claims directed to disclosure that isn’t claimed in this patent.